Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accumulated Expenses (2016 - 2025)

Collegium Pharmaceutical has reported Accumulated Expenses over the past 10 years, most recently at $62.5 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $62.5 million for Q4 2025, down 13.39% from a year ago — trailing twelve months through Dec 2025 was $62.5 million (down 13.39% YoY), and the annual figure for FY2025 was $62.5 million, down 13.39%.
  • Accumulated Expenses for Q4 2025 was $62.5 million at Collegium Pharmaceutical, up from $2.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for COLL hit a ceiling of $72.1 million in Q4 2024 and a floor of $968000.0 in Q1 2024.
  • Median Accumulated Expenses over the past 5 years was $2.9 million (2023), compared with a mean of $13.0 million.
  • Biggest five-year swings in Accumulated Expenses: surged 2836.46% in 2024 and later plummeted 93.94% in 2025.
  • Collegium Pharmaceutical's Accumulated Expenses stood at $3.2 million in 2021, then tumbled by 33.89% to $2.1 million in 2022, then surged by 134.13% to $5.0 million in 2023, then soared by 1346.24% to $72.1 million in 2024, then dropped by 13.39% to $62.5 million in 2025.
  • The last three reported values for Accumulated Expenses were $62.5 million (Q4 2025), $2.9 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.